Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NVCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $34.13
Previous CloseN/A
Volume205.01K
Average Volume (3M)965.07K
Market Cap
$1.93B
Enterprise Value$2.95B
Total Cash (Recent Filing)$57.61M
Total Debt (Recent Filing)$321.00K
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Apr 24, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding109,915,430
10 Day Avg. Volume629,737
30 Day Avg. Volume965,072
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.51
Price to Cash Flow (P/CF)-153.90
P/FCF Ratio346.30
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.31
Enterprise Value/Ebitda-27.46
Forecast
1Y Price Target
$38.20Price Target Upside112.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
NovoCure News
PremiumCompany Announcements
Novocure Reports Strong 2024 Revenue GrowthPremiumCompany Announcements
NovoCure’s Earnings Call: Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe successful Phase 3 PANOVA-3 trial in pancreatic cancer demonstrated a statistically significant improvement in overall survival, strengthening the clinical evidence supporting TTFields therapy.
Regulatory ApprovalsThe FDA granted Breakthrough Device designation for TTFields therapy in both brain metastases from NSCLC and unresectable, locally advanced pancreatic cancer, potentially accelerating market entry.
Revenue GrowthPreliminary Q4 revenue exceeded expectations, largely driven by collection of aged accounts.
Bears Say
Prescription DeclinePrescriptions for Optune Gio shrunk overall in 4Q24 with 1,520 received in the quarter compared to 1,586 in 3Q24, a 4% decrease.
Revenue ChallengesRevenue in Greater China was below estimates and represented only about half of historical quarterly revenue.
---
Ownership Overview
1.82% Insiders
35.53% Mutual Funds
25.14% Other Institutional Investors
21.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $11.70 and its highest was $34.13 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.93B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Apr 24, 2025 which is in 20 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Feb 27, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.344 by -$0.266.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.49.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 109,915,430 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.344. Following the earnings report the stock price went down -12.432%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
---
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.20 (112.93% Upside)
$38.20 (112.93% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 59.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $736.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.66%
12-Months-Change
Fundamentals
Return on Equity
-46.67%
Trailing 12-Months
Asset Growth
8.26%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
NovoCure's earnings call reflects strong overall performance and significant achievements, particularly in expanding indications and clinical trial successes. However, challenges with reimbursement, increased operating expenses, and potential gross margin headwinds indicate areas of concern that need to be addressed.Read More>---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$38.20
▲(112.93% Upside)
Technical Analysis
Insulet
―
Integra Lifesciences
―
QuidelOrtho
―
Zimmer Biomet Holdings
―
Tandem Diabetes Care
―
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+13.32%
reiterated a buy rating last month
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +13.32% per trade.
---